Program
evofosfamide
Also written as “TH-302”, “Evofosfamide” and “TH-302 combination with pemetrexed”.
Its studies are mostly in Sarcoma · Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Prostatic Neoplasms · Melanoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Threshold Pharmaceuticals | 80 open or running | phase 3since Sep 20, 2011 | Jun 28, 2007 | none ahead |
| ImmunoGenesis | 71 open or running | phase 3since Dec 7, 2012 | Aug 26, 2008 | Oct 2027phase 2 · NCT06782555 |
| Merck KGaA, Darmstadt, Germany | 20 open or running | phase 2since Sep 30, 2014 | Feb 20, 2014 | none ahead |
Also a collaborator on its studies: Agenus and pra-health-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jun 28, 2007.
- Jun 1, 2010Phase 1 study in Leukemia, Myeloid, AcuteThreshold Pharmaceuticals · NCT01149915 · 40 enrolled · United States
- Jun 11, 2010Phase 2 study in Pancreatic AdenocarcinomaImmunoGenesis · NCT01144455 · 214 enrolled · United States
- Jun 23, 2011Phase 1 study in Gastrointestinal Stromal TumorsThreshold Pharmaceuticals · NCT01381822 · 58 enrolled · United States
- Sep 20, 2011Phase 3 study in SarcomaThreshold Pharmaceuticals · NCT01440088 · 640 enrolled · United States, Austria, Belgium and more
- Jan 6, 2012Phase 2 study in Multiple MyelomaThreshold Pharmaceuticals · NCT01522872 · 98 enrolled · United States
- Dec 7, 2012Phase 3 study in Neoplasm MetastasisImmunoGenesis · NCT01746979 · 693 enrolled · United States, Germany
- May 13, 2013Phase 2 study in MelanomaImmunoGenesis · NCT01864538 · 11 enrolled · United States, Canada
- Nov 14, 2013Phase 1 study in Solid TumorsThreshold Pharmaceuticals · NCT02020226 · 40 enrolled · United States
- Jan 24, 2014Phase 1 study in Pancreatic NeoplasmsImmunoGenesis · NCT02047500 · 19 enrolled · United States
- Feb 20, 2014Merck KGaA, Darmstadt, Germany's first study: phase 1 study in Solid TumorNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT02076230 · 10 enrolled · Germany
- Mar 18, 2014Phase 2 study in Carcinoma, Non-Small-Cell LungImmunoGenesis · NCT02093962 · 265 enrolled · United States, Czechia, Germany and more
- Sep 30, 2014Phase 2 study in SarcomaMerck KGaA, Darmstadt, Germany · NCT02255110 · 6 enrolled · Japan
- Mar 22, 2017Phase 1 study in Pancreatic NeoplasmsThreshold Pharmaceuticals · NCT03098160 · 69 enrolled · United States
- Jan 9, 2025Phase 2 study in Prostatic NeoplasmsImmunoGenesis · NCT06782555 · 71 enrolled · United States
Ahead
- Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsImmunoGenesis · NCT06782555
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06782555Prostatic Neoplasms · United States | 2 | Active, not recruiting | ImmunoGenesis | Oct 2027 | 71 |
| NCT03098160Pancreatic Neoplasms · United States | 1 | UNKNOWN | Threshold Pharmaceuticals | Jan 2019 | 69 |
| NCT02255110Sarcoma · Japan | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Jan 12, 2016 | 6 |
| NCT02093962Carcinoma, Non-Small-Cell Lung · United States, Czechia, Germany and more | 2 | Terminated | ImmunoGenesis | Apr 2016 | 265 |
| NCT02076230Solid Tumor · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Sep 2014 | 10 |
| NCT02047500Pancreatic Neoplasms · United States | 1 | Terminated | ImmunoGenesis | Sep 2015 | 19 |
| NCT02020226Solid Tumors · United States | 1 | UNKNOWN | Threshold Pharmaceuticals | Jul 2016 | 40 |
| NCT01864538Melanoma · United States, Canada | 2 | Terminated | ImmunoGenesis | Sep 2015 | 11 |
| NCT01746979Neoplasm Metastasis · United States, Germany | 3 | Completed | ImmunoGenesis | Feb 2016 | 693 |
| NCT01522872Multiple Myeloma · United States | 2 | UNKNOWN | Threshold Pharmaceuticals | Sep 2016 | 98 |
| NCT01440088Sarcoma · United States, Austria, Belgium and more | 3 | Completed | Threshold Pharmaceuticals | Dec 2015 | 640 |
| NCT01381822Gastrointestinal Stromal Tumors · United States | 1 | UNKNOWN | Threshold Pharmaceuticals | Jun 2014 | 58 |
| NCT01144455Pancreatic Adenocarcinoma · United States | 2 | Completed | ImmunoGenesis | Sep 2013 | 214 |
| NCT01149915Leukemia, Myeloid, Acute · United States | 1 | Completed | Threshold Pharmaceuticals | Aug 2013 | 40 |
| NCT00743379Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Threshold Pharmaceuticals | Jul 2013 | 71 |
| NCT00742963Sarcoma · United States | 2 | Completed | ImmunoGenesis | Jul 2013 | 107 |
| NCT00495144Neoplasms · United States | 1 | Completed | Threshold Pharmaceuticals | Dec 2011 | 129 |
How it is read
Names in the registry
- “TH-302”, 13 entries
- “Evofosfamide”, 2 entries
- “TH-302 combination with pemetrexed”, 1 entry
- “[14C] TH-302 (Label 1)”, 1 entry
- “[14C] TH-302 (Label 2)”, 1 entry
Conditions, from the studies’ own filings
- Sarcoma, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Pancreatic Neoplasms, 2 studies
- Prostatic Neoplasms, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.